As of 2025-12-27, the Relative Valuation of Akebia Therapeutics Inc (AKBA) is (1.14) USD. This relative valuation is based on P/E multiples. With the latest stock price at 1.66 USD, the upside of Akebia Therapeutics Inc based on Relative Valuation is -168.7%.
The range of the Relative Valuation is (1.04) - (1.39) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.3x - 23.1x | 20.0x |
| Forward P/E multiples | 17.4x - 25.6x | 18.1x |
| Fair Price | (1.04) - (1.39) | (1.14) |
| Upside | -162.9% - -183.5% | -168.7% |
| Date | P/E |
| 2025-12-26 | -27.70 |
| 2025-12-24 | -28.36 |
| 2025-12-23 | -27.53 |
| 2025-12-22 | -27.70 |
| 2025-12-19 | -27.70 |
| 2025-12-18 | -27.86 |
| 2025-12-17 | -26.86 |
| 2025-12-16 | -27.03 |
| 2025-12-15 | -26.86 |
| 2025-12-12 | -27.70 |
| 2025-12-11 | -27.70 |
| 2025-12-10 | -27.20 |
| 2025-12-09 | -26.36 |
| 2025-12-08 | -27.03 |
| 2025-12-05 | -25.69 |
| 2025-12-04 | -26.53 |
| 2025-12-03 | -26.19 |
| 2025-12-02 | -24.53 |
| 2025-12-01 | -25.19 |
| 2025-11-28 | -26.36 |
| 2025-11-26 | -26.53 |
| 2025-11-25 | -26.19 |
| 2025-11-24 | -26.53 |
| 2025-11-21 | -25.86 |
| 2025-11-20 | -25.69 |
| 2025-11-19 | -26.53 |
| 2025-11-18 | -27.53 |
| 2025-11-17 | -29.37 |
| 2025-11-14 | -27.86 |
| 2025-11-13 | -29.37 |
| 2025-11-12 | -30.87 |
| 2025-11-11 | -30.20 |
| 2025-11-10 | -27.86 |
| 2025-11-07 | -34.04 |
| 2025-11-06 | -33.54 |
| 2025-11-05 | -35.37 |
| 2025-11-04 | -34.87 |
| 2025-11-03 | -35.37 |
| 2025-10-31 | -36.87 |
| 2025-10-30 | -35.04 |
| 2025-10-29 | -35.04 |
| 2025-10-28 | -51.56 |
| 2025-10-27 | -52.89 |
| 2025-10-24 | -50.55 |
| 2025-10-23 | -49.72 |
| 2025-10-22 | -49.89 |
| 2025-10-21 | -52.06 |
| 2025-10-20 | -52.72 |
| 2025-10-17 | -48.89 |
| 2025-10-16 | -48.72 |